Surveyed U.S. Neurologists Are More Likely Than Payers to Consider Biogen ... PR Newswire (press release) The report also finds that novel late-stage emerging disease-modifying therapies (DMTs) for the treatment of MS—Genzyme/Bayer HealthCare's Lemtrada, Biogen Idec/AbbVie's daclizumab and Roche/Genentech's ocrelizumab—will generally be reserved for ... |
